<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803006</url>
  </required_header>
  <id_info>
    <org_study_id>TCD601A201</org_study_id>
    <nct_id>NCT04803006</nct_id>
  </id_info>
  <brief_title>A Study of TCD601 in the Induction of Tolerance in de Novo Renal Transplantation (PANORAMA)</brief_title>
  <official_title>An Adaptive, Regimen Finding, Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-myeloablative Conditioning, for Tolerance Induction in de Novo Living Donor Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ITB-Med LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ITB-Med LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the optimal regimen for the use of siplizumab, a&#xD;
      human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative&#xD;
      conditioning, for tolerance induction in de novo living donor renal transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">August 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The optimal regimen for renal allograft tolerance while minimizing chimeric transition syndrome</measure>
    <time_frame>24 months</time_frame>
    <description>The proportion of patients off immunossupression with good safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of biopsy proven acute rejection, death and graft loss</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of de novo donor-specific antibody</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TCD601administered with non-myeloablative conditioning and standard of care immunosuppression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TCD601administered with non-myeloablative conditioning and standard of care immunosuppression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TCD601administered with non-myeloablative conditioning and standard of care immunosuppression</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TCD601</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand the study requirements and provide written informed consent before&#xD;
             and study assessment is performed&#xD;
&#xD;
          -  Male or female patients â‰¥ 18 to 60 years of age&#xD;
&#xD;
          -  Recipient of a first or second renal transplant from a non-HLA identical, but at least&#xD;
             haploidentical, ABO compatible living donor&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Women of child-bearing potential&#xD;
&#xD;
          -  Subjects with a history of cancer&#xD;
&#xD;
          -  Donor-specific Antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kellie Kennon, BSN</last_name>
    <phone>212-969-7823</phone>
    <email>ktx@itb-med.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>March 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

